Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism
- PMID: 23916504
- DOI: 10.1016/j.euroneuro.2013.07.001
Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: a potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism
Abstract
We previously reported that the investigational multimodal antidepressant, vortioxetine, reversed 5-HT depletion-induced memory deficits while escitalopram and duloxetine did not. The present report studied the effects of vortioxetine and the potential impact of its 5-HT1A receptor agonist and 5-HT3 receptor antagonist properties on 5-HT depletion-induced memory deficits. Recognition and spatial working memory were assessed in the object recognition (OR) and Y-maze spontaneous alternation (SA) tests, respectively. 5-HT depletion was induced in female Long-Evans rats using 4-cholro-DL-phenylalanine methyl ester HCl (PCPA) and receptor occupancies were determined by ex vivo autoradiography. Rats were acutely dosed with vortioxetine, ondansetron (5-HT3 receptor antagonist) or flesinoxan (5-HT1A receptor agonist). The effects of chronic vortioxetine administration on 5-HT depletion-induced memory deficits were also assessed. 5-HT depletion reliably impaired memory performance in both the tests. Vortioxetine reversed PCPA-induced memory deficits dose-dependently with a minimal effective dose (MED) ≤0.1mg/kg (∼80% 5-HT3 receptor occupancy; OR) and ≤3.0mg/kg (5-HT1A, 5-HT1B, 5-HT3 receptor occupancy: ∼15%, 60%, 95%) in SA. Ondansetron exhibited a MED ≤3.0μg/kg (∼25% 5-HT3 receptor occupancy; OR), but was inactive in the SA test. Flesinoxan had a MED ≤1.0mg/kg (∼25% 5-HT1A receptor occupancy; SA); only 1.0mg/kg ameliorated deficits in the NOR. Chronic p.o. vortioxetine administration significantly improved memory performance in OR and occupied 95%, 66%, and 9.5% of 5-HT3, 5-HT1B, and 5-HT1A receptors, respectively. Vortioxetine's effects on SA performance may involve 5-HT1A receptor agonism, but not 5-HT3 receptor antagonism, whereas the effects on OR performance may involve 5-HT3 receptor antagonism and 5-HT1A receptor agonism.
Keywords: 5-HT depletion; 5-HT(1A) receptor; 5-HT(3) receptor; Cognitive dysfunction; Major depressive disorder; Vortioxetine.
Copyright © 2013 Elsevier B.V. and ECNP. All rights reserved.
Similar articles
-
Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats.Int J Neuropsychopharmacol. 2014 Oct;17(10):1695-706. doi: 10.1017/S1461145714000571. Epub 2014 May 23. Int J Neuropsychopharmacol. 2014. PMID: 24852131 Free PMC article.
-
Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation.Eur Neuropsychopharmacol. 2014 Jan;24(1):148-59. doi: 10.1016/j.euroneuro.2013.10.011. Epub 2013 Nov 4. Eur Neuropsychopharmacol. 2014. PMID: 24284262
-
Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism.J Psychopharmacol. 2015 Oct;29(10):1092-105. doi: 10.1177/0269881115592347. Epub 2015 Jul 14. J Psychopharmacol. 2015. PMID: 26174134 Free PMC article.
-
Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.Pharmacol Ther. 2015 Jan;145:43-57. doi: 10.1016/j.pharmthera.2014.07.001. Epub 2014 Jul 9. Pharmacol Ther. 2015. PMID: 25016186 Review.
-
[Pharmacological properties of vortioxetine and its pre-clinical consequences].Encephale. 2016 Feb;42(1 Suppl 1):1S12-23. doi: 10.1016/S0013-7006(16)30015-X. Encephale. 2016. PMID: 26879252 Review. French.
Cited by
-
Effectiveness of vortioxetine in patients with major depressive disorder and comorbid Alzheimer's disease in routine clinical practice: An analysis of a post-marketing surveillance study in South Korea.Front Aging Neurosci. 2023 Jan 9;14:1037816. doi: 10.3389/fnagi.2022.1037816. eCollection 2022. Front Aging Neurosci. 2023. PMID: 36698860 Free PMC article.
-
Vortioxetine as a new frontier in the treatment of chronic neuropathic pain: a review and update.Ther Adv Psychopharmacol. 2021 Sep 3;11:20451253211034320. doi: 10.1177/20451253211034320. eCollection 2021. Ther Adv Psychopharmacol. 2021. PMID: 34497709 Free PMC article. Review.
-
Use of vortioxetine in different neurological fields: a systematic review and future perspectives.Neurol Sci. 2025 May;46(5):2055-2071. doi: 10.1007/s10072-025-07987-1. Epub 2025 Jan 14. Neurol Sci. 2025. PMID: 39808348
-
Vortioxetine Modulates the Regional Signal in First-Episode Drug-Free Major Depressive Disorder at Rest.Front Psychiatry. 2022 Jun 29;13:950885. doi: 10.3389/fpsyt.2022.950885. eCollection 2022. Front Psychiatry. 2022. PMID: 35845440 Free PMC article.
-
Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats.Int J Neuropsychopharmacol. 2014 Oct;17(10):1695-706. doi: 10.1017/S1461145714000571. Epub 2014 May 23. Int J Neuropsychopharmacol. 2014. PMID: 24852131 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical